MoonLake Immunotherapeutics (MLTX) Cash from Financing Activities (2021 - 2026)

MoonLake Immunotherapeutics' Cash from Financing Activities history runs 6 years deep, the most recent figure standing at $30.6 million for Q1 2026.

• In Q1 2026, Cash from Financing Activities fell 58.09% year-over-year to $30.6 million; the TTM figure through Mar 2026 stood at $103.5 million (up 40.93% YoY), while the FY2025 annual figure was $146.0 million, up 184.53% from the prior year.
• Cash from Financing Activities was $30.6 million for Q1 2026 at MoonLake Immunotherapeutics, down from $72.4 million in the prior quarter.
• In the past five years, Cash from Financing Activities ranged from a high of $451.3 million in Q2 2023 to a low of $3791.0 in Q4 2022.
• Historically, Cash from Financing Activities has averaged $68.9 million across 5 years, with a median of $29.5 million in 2023.
• The sharpest annual moves came in 2022 and 2023: Cash from Financing Activities tumbled 99.99% in 2022, then jumped 749462.31% in 2023.
• A 5-year view of Cash from Financing Activities shows it stood at $3791.0 in 2022, then surged by 749462.31% to $28.4 million in 2023, then tumbled by 99.47% to $151000.0 in 2024, then soared by 47843.71% to $72.4 million in 2025, then plunged by 57.67% to $30.6 million in 2026.
• The last three Cash from Financing Activities figures came in at $30.6 million (Q1 2026), $72.4 million (Q4 2025), and $480000.0 (Q3 2025), per Business Quant data.